Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

ne reduced negative symptoms after one year of treatment, but the difference between the two was not statistically significant.(1)

Additionally, a preliminary pooled analysis of the combined data for these two identically designed studies showed a statistically significant treatment effect in favor of asenapine after one year of treatment.

These large Phase III studies were conducted following a previous Phase II study where favorable data on negative symptoms were observed for asenapine.

About the study

This study was a 26-week extension of a randomized, double-blind, multicentered, multinational 26-week clinical trial evaluating the efficacy and safety of SAPHRIS compared to olanzapine in the treatment of patients with stable predominant, persistent negative symptoms of schizophrenia. Patients were initially randomized in the core study to SAPHRIS 5 to 10 mg twice daily or olanzapine 5 to 20 mg once daily for 26 weeks. In the core study, both SAPHRIS and olanzapine reduced negative symptoms over the 26-week treatment period, but the difference between the two was not statistically significant. Patients who continued after six months were maintained on the same double-blind treatment regimen for the 26-week extension study. In the extension study, SAPHRIS demonstrated statistically significantly greater change in NSA-16 total score from the core study baseline after one year of treatment, the primary prespecified endpoint of the extension study. A total of 468 patients were randomized in the core study, 195 of whom entered the extension study, with 146 completing a total of one year of treatment.

In the study, the most common adverse events reported for the SAPHRIS group (greater than 5 percent) during the one year treatment period were: insomnia, somnolence, weight increase, anxiety, headache, weight decrease, akathisia, diarrhea, dizziness, fatigue, nasopharyngit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Paul, Minn. (PRWEB) March 05, 2015 ... in Pasadena this summer at the Annual Meeting of ... are starting to be released online now at ... been announced for the meeting, to be held August ... newly announced Special Sessions, Field Trips, Workshops, and committee ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... and TORONTO , March 5, 2015 ... clinical-stage company developing new therapeutics and molecular diagnostics that ... William G. Rice , Ph.D., Chairman, President and ... Annual ROTH Conference on Tuesday, March 10 th ... Laguna Niguel, CA. Dr. Rice ...
(Date:3/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ... Biotech Outlook 2015: New Therapy Ventures Pave the Way ... All biotech companies - Gilead (GILD), Amgen (AMGN), ... have given a positive return and hence increased the ... to select therapy/niche indication where the high treatment cost ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... - Vaccine for new strain of virus broadens government ... April 28 ,Sanofi Pasteur, the vaccines division of sanofi-aventis ... Human Services (HHS) has,accepted H5N1 bulk vaccine antigen to ... a new strain of avian influenza. Sanofi,Pasteur has a ...
... boost cellular energy, NEW YORK, April 28 Ever ... and not catch up? That,s how Holly Jacobson, a nurse,in ... reason to be,exhausted -- five boys under the age of ... a sixth son, and she began experiencing palpitations,breathlessness and fatigue ...
... 28 Campbell Alliance, the leading,management consulting ... today announced that Doug Linton has joined ... up of industry professionals brought,together by Campbell ... expertise,to highly complex engagements. Mr. Linton will ...
Cached Biology Technology:U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4D-Ribose Helps Energy-Starved Hearts 2Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group 2Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group 3
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:2/24/2015)... -- This report analyzes the worldwide markets for Face and Voice ... Voice Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Latin America . Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2
... certain viruses. Some viruses can be lethal to pest ... harming beneficial insects or other organisms. Hence they are ... protection worldwide. The proverbial worm in the apple, the ... for years with a baculovirus called codling moth granulovirus ...
... Acid rain was one of the worlds worst pollution problems ... Britain, as well as Europe and North America. In ... been acidified, harming fish, stream insects and river birds such ... has been taken across Europe to clean up acid pollutants ...
... ESAs Member States participating in the GMES Programme approved ... GMES Space Component Programme. Oversubscription of the programme ... was confirmed, with oversubscription to phase 2 of 116%, ... contribution to the programme will allow ESA to confirm ...
Cached Biology News:Surprise in the organic orchard -- a healthier worm in the apple 2Recovery from acid rain 'much slower than expected' 2
... BioControl multichannel has the ... the single channel model.The ... allseven multichannel and five ... modules. Both pipettes have ...
... is pleased to offer the ATTO-TAG ... detection of primary amines. Developed by ... the ATTO-TAG reagents are similar to ... (NDA) and anthracene-2,3-dicarboxaldehyde, all of which ...
...
...
Biology Products: